Scholarlink

<p>Hyperuricemia, resulting from impaired purine metabolism, is a metabolic health concern associated with gout and related disorders. Non-pharmacological strategies remain limited, underscoring the need for probiotic-based dietary interventions. The objective of this study was to identify purine-degrading lactic acid bacteria (LAB) with probiotic potential for managing hyperuricemia. Thirty-one LAB strains were isolated from fermented foods and <i>Ficus carica</i>. Of these, 16 strains showing detectable uric acid absorption were retained, and seven strains exhibiting &gt; 15% uric acid absorption underwent detailed enzymatic profiling, including (XOD) xanthine oxidase inhibition, (UOX) urate oxidase activity (<i>p</i> &lt; 0.05 vs. control), and 16&#xa0;S rRNA sequencing. Among these, five strains (F7, F8, S1, S3, B3) that achieved &gt; 90% inosine and guanosine degradation were selected for probiotic characterization. Enzyme profiling identified <i>Lactiplantibacillus plantarum</i> F7 as the most potent strain, showing dual activity (UOX: 0.55 ± 0.04 U/mg protein; XOD: 0.32 ± 0.03 U/mg protein) and high nucleoside degradation efficiencies (98.59 ± 0.50%) for inosine and (99.19 ± 0.47%) for guanosine with degradation velocities of 10.35 ± 0.05 and 10.41 ± 0.04&#xa0;mg/(L·min). Probiotic assessment revealed robust acid tolerance (84.27% survival at pH 2), high bile resistance (&gt; 90% at 0.3%), strong antioxidant capacity, negligible purine production, antibiotic susceptibility, and non-hemolytic activity. All experiments were performed in triplicate (<i>n</i> = 3), with results expressed as mean ± SD and analyzed using ANOVA with Tukey’s post-hoc test. These findings identify <i>Lpb. plantarum</i> F7 as a promising probiotic candidate for managing hyperuricemia. This study was in vitro; in vivo validation is required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Purine-Degrading Lactic Acid Bacteria Isolated from Fermented Foods and Fig Fruit: Evaluation of Probiotic and Anti-Hyperuricemic Properties

  • 期刊论文

  • 发表日期：

    2025年11月28日

查看全文
  • Tanzila Asjad,
  • Abdulqader Al-Adeeb,
  • Madjidi Sibomana,
  • Samra Basharat,
  • Erum Bux,
  • Qiuya Gu,
  • Xiaobin Yu

摘要

Hyperuricemia, resulting from impaired purine metabolism, is a metabolic health concern associated with gout and related disorders. Non-pharmacological strategies remain limited, underscoring the need for probiotic-based dietary interventions. The objective of this study was to identify purine-degrading lactic acid bacteria (LAB) with probiotic potential for managing hyperuricemia. Thirty-one LAB strains were isolated from fermented foods and Ficus carica. Of these, 16 strains showing detectable uric acid absorption were retained, and seven strains exhibiting > 15% uric acid absorption underwent detailed enzymatic profiling, including (XOD) xanthine oxidase inhibition, (UOX) urate oxidase activity (p < 0.05 vs. control), and 16 S rRNA sequencing. Among these, five strains (F7, F8, S1, S3, B3) that achieved > 90% inosine and guanosine degradation were selected for probiotic characterization. Enzyme profiling identified Lactiplantibacillus plantarum F7 as the most potent strain, showing dual activity (UOX: 0.55 ± 0.04 U/mg protein; XOD: 0.32 ± 0.03 U/mg protein) and high nucleoside degradation efficiencies (98.59 ± 0.50%) for inosine and (99.19 ± 0.47%) for guanosine with degradation velocities of 10.35 ± 0.05 and 10.41 ± 0.04 mg/(L·min). Probiotic assessment revealed robust acid tolerance (84.27% survival at pH 2), high bile resistance (> 90% at 0.3%), strong antioxidant capacity, negligible purine production, antibiotic susceptibility, and non-hemolytic activity. All experiments were performed in triplicate (n = 3), with results expressed as mean ± SD and analyzed using ANOVA with Tukey’s post-hoc test. These findings identify Lpb. plantarum F7 as a promising probiotic candidate for managing hyperuricemia. This study was in vitro; in vivo validation is required.